Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in via BCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Browse by collection
Authors
Podcasts
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Browse by collection
Authors
Podcasts
About
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in via BCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 108, Issue 16
BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Editorial
BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk
Online download statistics by month:
Online download statistics by month: May 2022 to March 2023
Abstract
Full
Pdf
May 2022
1288
67
28
Jun 2022
453
23
11
Jul 2022
1331
88
39
Aug 2022
751
84
36
Sep 2022
561
36
15
Oct 2022
202
16
11
Nov 2022
1159
20
12
Dec 2022
161
7
7
Jan 2023
151
10
11
Feb 2023
217
11
7
Total
6274
362
177
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in via BCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF